Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Hepatitis A vaccination

M J Tong¹, R L Co, C Bellak

¹Liver Center, Huntington Memorial Hospital, Pasadena, California 91109-7013.

The Western Journal of Medicine

|June 1, 1993

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Editorial: an expert consensus for the management of chronic hepatitis B in Asian Americans-Authors' reply.

Alimentary pharmacology & therapeutics·2018

Same author

An expert consensus for the management of chronic hepatitis B in Asian Americans.

Alimentary pharmacology & therapeutics·2018

Same author

Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B.

Transplantation proceedings·2007

Same author

Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2006

Same author

A systems comparison of once- versus twice-daily milking of pastured dairy cows.

Journal of dairy science·2006

Same author

Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America.

Journal of gastroenterology and hepatology·2001

Same journal

Does daily use of sunscreen or beta-carotene supplements prevent skin cancer in healthy adults?

The Western journal of medicine·2008

Same journal

[Not Available].

The Western journal of medicine·2008

Same journal

[Not Available].

The Western journal of medicine·2008

Same journal

[Not Available].

The Western journal of medicine·2008

Same journal

[Not Available].

The Western journal of medicine·2008

Same journal

[Not Available].

The Western journal of medicine·2008

See all related articles

This study shows an inactivated hepatitis A vaccine is safe and highly immunogenic in healthy adults. All participants achieved protective antibody titers after two doses, with higher responses in younger individuals and those on a 12-month booster schedule.

Area of Science:

Immunology
Vaccinology
Virology

Background:

Hepatitis A virus (HAV) infection is a global health concern.
Assessing the safety and immunogenicity of inactivated HAV vaccines is crucial for public health strategies.

Purpose of the Study:

To evaluate the safety and immunogenicity of an inactivated hepatitis A virus vaccine in healthy adults.
To compare the immunogenicity between different age groups and vaccination schedules.

Main Methods:

101 healthy, seronegative adults were enrolled and divided into four groups based on age and vaccination schedule.
Two schedules were used: Schedule A (0, 1, and 2 months) and Schedule B (0, 1, and 12 months).
Antibody titers to hepatitis A virus were measured after vaccination.

Related Experiment Videos

Main Results:

97% seroconverted after the first dose, and 100% after the second dose.
Higher geometric mean titers (GMTs) were observed in younger adults (<40 years) compared to older adults (>40 years) across both schedules.
Schedule B (12-month booster) resulted in significantly higher GMTs than Schedule A in both age groups.
The vaccine was well-tolerated, with mild injection site discomfort as the primary side effect.

Conclusions:

The inactivated hepatitis A virus vaccine is safe and highly immunogenic in healthy adults.
Vaccination elicits a robust immune response, with younger individuals and those receiving a 12-month booster showing enhanced antibody titers.
The findings support the efficacy of this vaccine for hepatitis A prevention across different age demographics and vaccination regimens.